Takeda Bets US$600M on Insilico’s AI for Drug Discovery

The collaboration leverages Insilico’s suite of digital tools, which include PandaOmics for biological target identification and Chemistry42 for molecular design. Under the terms of the agreement, Insilico will spearhead the AI-driven discovery process, while Takeda assumes responsibility for advancing promising candidates through clinical trials and eventual manufacturing. The financial structure includes US$60 million in upfront and near-term payments, with the remaining balance tied to specific preclinical, clinical, and commercial milestones, alongside tiered royalties on future sales.

This partnership marks Takeda’s second major foray into AI-assisted research this year, following a US$1.7 billion collaboration with Iambic established in February. Chris Arendt, Takeda’s chief scientific officer, noted that the integration of generative AI and robotics is now a central component of the company’s broader research strategy. For Insilico, the deal adds to a string of high-profile agreements signed this year, including recent collaborations with Eli Lilly and SK Biopharmaceuticals, contributing to a total potential deal value exceeding US$7 billion. Following the announcement, Insilico’s shares climbed 13.5%.